Back to top
more

Amicus Therapeutics (FOLD)

(Real Time Quote from BATS)

$11.34 USD

11.34
126,285

+0.01 (0.09%)

Updated Nov 5, 2024 10:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised

Vertex's third-quarter 2024 earnings and revenues beat estimates. The company raises its full-year product revenue guidance.

AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates

AbCellera Biologics (ABCL) delivered earnings and revenue surprises of -21.43% and 27.30%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know

The consensus price target hints at a 51.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Perrigo to Report Q3 Earnings: Here's What to Expect

PRGO's Q3 top line is expected to have been affected by lower net product sales in the United States and unfavorable currency movements in the quarter.

Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales

BHC's third-quarter adjusted earnings and revenues beat estimates. The increase in revenue guidance is positive.

AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down

Agios' third-quarter 2024 earnings miss estimates while revenues match the same. Shares fall.

United Therapeutics Q3 Earnings & Sales Beat Estimates

UTHR reports better-than-expected results in third-quarter 2024 on the back of strong demand for its treprostinil medications, especially Tyvaso.

Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus

Kymera reports a narrower-than-expected loss in the third quarter. The company expects the current cash balance to provide a runway into mid-2027.

HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up

Halozyme reports better-than-expected third-quarter 2024 results. The company raises revenue guidance for 2024. Stock rises in after-hours trading.

Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates

INSM posts wider-than-expected Q3 loss. The company plans to meet the FDA before 2024-end to discuss the possibility of an accelerated approval to expand Arikayce's label.

Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View

BMY posts impressive third-quarter results, with both earnings and sales beating the respective estimates. The company also raises its annual earnings guidance.

Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know

Mirum Pharmaceuticals (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View

CORT beats on both earnings and sales in the third quarter of 2024. The company increases the revenue guidance for 2024. Stock falls in after-hours trading.

Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates

AMRN's third-quarter 2024 earnings meet estimates while revenues miss the same. Vascepa's sales in the United States decline year over year. Stock falls.

Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Incyte (INCY) Q3 Earnings Miss Estimates

Incyte (INCY) delivered earnings and revenue surprises of -4.46% and 4.47%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

GitLab and Baidu have been highlighted as Zacks Bull and Bear of the Day

GitLab and Baidu have been highlighted as Zacks Bull and Bear of the Day.

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma

Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma have been highlighted in this Industry Outlook article.

Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More

FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.

Best Momentum Stocks to Buy for October 24th

FOLD, CLPR and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 24, 2024.

VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline Advancements

Viking Therapeutics' third-quarter earnings outpace estimates. The company plans to start a mid-stage study on its obesity pill before 2024-end.

Ekta Bagri headshot

5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.

New Strong Buy Stocks for October 24th

CLPR, HROW, FOLD, GTLB and TCOM have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2024.

NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients

A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients compared to placebo.

NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B

The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk's Alhemo for haemophilia A or B with inhibitors.